ClinicalTrials.gg
CompletedNCT03416179BRIGHT AML1019Updated Apr 21, 2023Results posted

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

A Phase 3 interventional study of glasdegib and daunorubicin + cytarabine in Leukemia, Myeloid, Acute, sponsored by Pfizer. Completed at 149 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.

Enrollment
5th of 48
730 · median 111
Started
2018
the only one that year
Phase 3
11 of 50
1 open now
Registered
36th of 50
by date

Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 5th largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2018, is one of 11 in phase 3, and was the 36th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About daunorubicin

Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).

Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Read the detailed description

Two separate registration trials conducted under one protocol number are proposed to adequately and independently evaluate the addition of glasdegib in intensive and non-intensive chemotherapy populations. Each study will have an experimental treatment arm and a placebo arm. Endpoints are the same for each study except where specifically indicated.

Assignment to the Intensive Study or the Non-Intensive Study will be made by the Investigator based on the 2017 European LeukemiaNet (ELN) recommendations.

Study B1371019 is a randomized (1:1), double-blind, multi-center, placebo controlled study of chemotherapy in combination with glasdegib versus chemotherapy in combination with placebo in adult patients with previously untreated AML.

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).

Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • glasdegib;
  • untreated;
  • Hedgehog Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the Intensive and Non Intensive study (unless where indicated):

  1. Subjects with untreated AML according to the World Health Organization (WHO) 2016 Classification2, including those with:

    • AML arising from MDS or another antecedent hematologic disease (AHD).
    • AML after previous cytotoxic therapy or radiation (secondary AML).
  2. 18 years of age (In Japan, 20 years of age).
  3. Adequate Organ Function as defined by the following:

    • Serum (AST) and serum alanine aminotransferase (ALT) 3 x (ULN), excluding subjects with liver function abnormalities due to underlying .
    • Total serum 2 x ULN (except subjects with documented Gilbert's syndrome).
    • Estimated 30 mL/min as calculated using the standard method for the institution.
  4. 470 msec using the Fridericia correction (QTcF).
  5. All anti cancer treatments (unless specified) should be discontinued 2 weeks from study entry, for example: targeted chemotherapy, radiotherapy, agents, hormones, anagrelide or cytokines.

    • For control of rapidly progressing leukemia, all trans retinoic acid (ATRA), hydroxyurea, and/or leukopheresis may be used before and for up to 1 week after the first dose of glasdegib.
  6. Serum or urine pregnancy test (for female subjects of ) with a minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin (hCG) negative at screening.
  7. Male and female subjects of childbearing potential and at risk for pregnancy must agree to use at least one highly effective method of throughout the study and for 180 days after the last dose of azacitidine, cytarabine, or daunorubicin; and the last dose of glasdegib or placebo, whichever occurs later.
  8. Female subjects of non childbearing potential must meet at least 1 of the following criteria:

    1. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    2. Have medically confirmed ovarian failure; or
    3. Achieved status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed by having a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state.

    All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.

  9. Consent to a saliva sample collection for a germline comparator, unless prohibited by local regulations or ethics committee (EC) decision.
  10. Evidence of a personally signed and dated document indicating that the patient has been informed of all pertinent aspects of the study.
  11. Subjects who are willing and able to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures (including bone marrow [BM] assessments).

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Acute Promyelocytic Leukemia (APL) and APLwith PML RARA, subjects (WHO 2016 classification).
  2. AML with BCR ABL1 or t(9;22)(q34;q11.2) as a sole abnormality.

    • Complex genetics may include t(9;22) cytogenetic translocation.
  3. Subjects with known active CNS leukemia.
  4. Participation in other clinical studies involving other drug(s) (Phases 1 4) within 4 weeks prior study entry and/or during study participation.
  5. Subjects known to be to or packed red cell transfusions per Institutional Guidelines, or a patient who refuses blood product support.
  6. Subjects with another active on treatment with the exception of basal cell carcinoma, non melanoma skin cancer, cervical carcinoma in situ. Other prior or concurrent malignancies will be considered on a case by case basis.
  7. Any one of the following ongoing or in the previous 6 months: myocardial infarction, congenital long syndrome, Torsades de pointes, symptomatic arrhythmias (including sustained ventricular tachyarrhythmia), right or left bundle branch block and bifascicular block, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF class III or IV), cerebrovascular accident, or symptomatic pulmonary embolism; as well as bradycardia defined as \<50 bpms.
  8. Subjects with an active, life threatening or uncontrolled systemic infection not related to AML.
  9. Subjects with (LVEF) \<50% are excluded from the Intensive Chemotherapy Study only.
  10. Cumulative anthracycline dose equivalent of 550 mg/m2 of daunorubicin for the Intensive Chemotherapy Study only.
  11. Known malabsorption syndrome or other condition that may significantly impair absorption of study medication in the investigator's judgment (eg, gastrectomy, lap band, Crohn's disease) and inability or unwillingness to swallow tablets or capsules.
  12. Current use or anticipated requirement for drugs that are known strong /5 inducers.
  13. Concurrent administration of herbal preparations.
  14. Major surgery or radiation within 4 weeks of starting study treatment.
  15. Documented or suspected to any one of the following:

    • For subjects assigned to intensive chemotherapy, documented or suspected hypersensitivity to cytarabine (not including drug fever or exanthema, including known cerebellar side effects) or daunorubicin.
    • For subjects assigned to non intensive chemotherapy, documented or suspected hypersensitivity to azacitidine or mannitol.
  16. Known active drug or alcohol abuse.
  17. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  18. Pregnant females or breastfeeding female subjects.
  19. Known recent or active suicidal ideation or behavior.
  20. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
730 participants (actual)

Study arms

  • Experimental
    Arm A (Intensive Study)

    Glasdegib + '7+3' Induction(s)

    Drug: glasdegib · Drug: daunorubicin + cytarabine · Drug: cytarabine · Procedure: HSCT

  • Placebo comparator
    Arm B (Intensive Study)

    Placebo + '7+3' Induction(s)

    Drug: daunorubicin + cytarabine · Drug: Placebo · Drug: cytarabine · Procedure: HSCT

  • Experimental
    Arm A (Non-intensive study)

    Glasdegib + azacitidine

    Drug: azacitidine · Drug: glasdegib

  • Placebo comparator
    Arm B (Non-intensive study)

    Placebo + azacitidine

    Drug: azacitidine · Drug: Placebo

Interventions

  • Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first. Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.

    Also known as: PF-04449913

  • Drugdaunorubicin + cytarabine

    Drug pages: Daunorubicin · Cytarabine

    '7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days). If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');

  • Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.

  • DrugPlacebo

    Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first. Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.

  • DrugPlacebo

    Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.

  • Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.

  • Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.

  • ProcedureHSCT

    If required, and done per standard of care post Induction(s).

06

What researchers measure

Primary outcomes

  1. Intensive Study: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.

    Time frame: Baseline up to 25 months

  2. Non-intensive Study: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.

    Time frame: Baseline up to 25 months

Secondary outcomes

  1. Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire

    MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 numeric rating scale (NRS), where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.

    Time frame: Post-baseline up to Week 8

  2. Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12

    MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.

    Time frame: Post-baseline up to Week 12

  3. Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)

    Complete remission (CR) was defined based on 2017 European LeukemiaNet (ELN) recommendations. CR: Bone marrow blasts \<5 percentage (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than equal to (\>=) 1.0\*10\^9/Liter (L); platelet count \>=100\*10\^9/L. CRMRD-neg: CR with negativity for a genetic marker by reverse transcription quantitative polymerase chain reaction (RT-qPCR), or CR with negativity by Multiparameter Flow Cytometry (MFC).

    Time frame: Day 1 up to maximum of 2 years

  4. Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)

    CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

    Time frame: Day 1 up to maximum of 3 years

  5. Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)

    CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

    Time frame: Day 1 up to maximum of 2 years

  6. Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)

    CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

    Time frame: Day 1 up to maximum of 3 years

  7. Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)

    CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC less than (\<) 1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.

    Time frame: Day 1 up to maximum of 2 years

  8. Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)

    CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \<1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.

    Time frame: Day 1 up to maximum of 3 years

  9. Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)

    MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.

    Time frame: Day 1 up to maximum of 2 years

  10. Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)

    MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.

    Time frame: Day 1 up to maximum of 3 years

  11. Intensive Study: Percentage of Participants With Partial Remission (PR)

    PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.

    Time frame: Day 1 up to maximum of 2 years

  12. Non-intensive Study: Percentage of Participants With Partial Remission (PR)

    PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.

    Time frame: Day 1 up to maximum of 3 years

  13. Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)

    CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

    Time frame: Day 1 up to maximum of 3 years

  14. Intensive Study: Duration of Response (DoRi)

    DoRi: only defined for participants who have ever achieved CRi or better (included CR as well) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. CRi: not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. Participants last known to be alive who were free from relapse after CRi or better were censored at the date of last disease assessment that verifies their status.

    Time frame: From date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause (maximum up to 2 years)

  15. Non-intensive Study: Duration of Response (DoRi) or (DoRh)

    DoRi: only defined for participants who have ever achieved CRi or better (included CR and CRh) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. DoRh: participants who had ever achieved CRh or better (included CR) on study as the time from date of first achieving CRh or better to the date of disease progression, or relapse after CRh or better, or death due to any cause. CRi: not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

    Time frame: From date of first achieving CRi/CRh or better to the date of relapse/disease progression after CRi/CRh or better or death due to any cause (maximum up to 3 years)

  16. Non-intensive Study: Time to Response

    TTRi:Participants who achieved CRi or better, as the time from date of randomization to first documentation of response(CRi or better).TTRh:Participants who achieved CRh or better, as the time from date of randomization to first documentation of response(CRh or better). CRi:not qualifying for CR, neutrophil\<0.5\*10\^9/L or platelets\<50\*10\^9, absence of extramedullary disease,absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

    Time frame: From the date of randomization to the first documentation of response (CRi/CRh or better) (maximum up to 3 years)

  17. Intensive Study: Event-free Survival (EFS)

    EFS: Time from the date of randomization to the date of treatment failure (TF), relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.

    Time frame: From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 2 years)

  18. Non-intensive Study: Event-free Survival (EFS)

    EFS: Time from the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.

    Time frame: From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 3 years)

  19. Intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score

    MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".

    Time frame: Day 1 up to maximum of 2 years

  20. Non-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score

    MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".

    Time frame: Day 1 up to maximum of 3 years

  21. Intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score

    EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL Group. It consists of the EQ-5D descriptive system and a visual analogue scale (VAS), the EuroQoL visual analogue scale (EQ-VAS). EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.

    Time frame: Day 1 up to maximum of 2 years

  22. Non-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score

    EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.

    Time frame: Day 1 up to maximum of 3 years

  23. Intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)

    EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Day 1 up to maximum of 2 years

  24. Non-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)

    EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Day 1 up to maximum of 3 years

  25. Intensive Study: Participants Global Impression of Symptoms (PGIS)

    PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".

    Time frame: Day 1 up to maximum of 2 years

  26. Non-intensive Study: Participants Global Impression of Symptoms (PGIS)

    PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".

    Time frame: Day 1 up to maximum of 3 years

  27. Intensive Study: Participants Global Impression of Change (PGIC)

    PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".

    Time frame: Day 1 up to maximum of 2 years

  28. Non-intensive Study: Participants Global Impression of Change (PGIC)

    PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".

    Time frame: Day 1 up to maximum of 3 years

  29. Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03

    AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

    Time frame: Day 1 up to maximum of 2 years

  30. Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03

    AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

    Time frame: Day 1 up to maximum of 3 years

  31. Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03

    A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

    Time frame: Day 1 up to maximum of 2 years

  32. Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03

    A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

    Time frame: Day 1 up to maximum of 3 years

  33. Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Hematology laboratory test included: anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 2 years

  34. Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Hematology laboratory test included: anemia, hemoglobin increased, INR increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 3 years

  35. Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, creatine phosphokinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 2 years

  36. Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, CPK increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 3 years

  37. Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 2 years

  38. Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03

    Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 3 years

  39. Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib

    Ctrough of Glasdegib was measured in nanogram per milliliter (ng/mL).

    Time frame: Induction, Day 10+/-1: pre-dose, 1, 4 hour (hr); Consolidation phase, Day 1: pre-dose, 1, 4 hr

  40. Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib

    Ctrough of Glasdegib was measured in ng/mL.

    Time frame: Pre-dose: Cycle 1 Day 15 and Cycle 2 Day 1

  41. Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 2 years

  42. Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.

    Time frame: Day 1 up to maximum of 3 years

07

Results

Posted Jun 25, 2021
Limitations and caveats
In this study, inadvertently a participant was counted twice for an non-SAE "Pyrexia" at PCD, at SCD update this duplicity has been rectified. Due to this reason total number of participants affected by non-SAE in non-intensive placebo arm was updated to "148".

Participant flow

This study evaluated glasdegib in intensive and non-intensive chemotherapy populations. Intensive study: Glasdegib was studied in combination with cytarabine and daunorubicin for the treatment of adult participants with previously untreated acute myeloid leukemia (AML). Non-intensive study: Glasdegib was studied in combination with azacitidine for the treatment of adult participants with previously untreated AML who were not candidates for intensive induction chemotherapy.

Participant flow — Overall Study
MilestoneIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Started201203163162
Treated198201162160
Completed01136
Not completed201202150156
Withdrew: Death9087117113
Withdrew: Withdrawal by subject152069
Withdrew: Lost to follow-up1103
Withdrew: Study participation terminated by sponsor93912631
Withdrew: Other2310

Outcome measures

PrimaryIntensive Study: Overall Survival (OS)

OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.

Time frame:
Baseline up to 25 months
Reported as:
Median · months
Intensive Study: Overall Survival (OS)
monthsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Overall Survival (OS)17.3 (15.2 to 18.5)20.4 (17.6 to NA)
Statistical analysis
  • Intensive Study: Glasdegib + Cytarabine + Daunorubicin vs Intensive Study: Placebo + Cytarabine + Daunorubicin · Log Rank · p = 0.6579 · Hazard ratio (hr): 1.08 · 95% CI 0.755 to 1.532
PrimaryNon-intensive Study: Overall Survival (OS)

OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.

Time frame:
Baseline up to 25 months
Reported as:
Median · months
Non-intensive Study: Overall Survival (OS)
monthsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Overall Survival (OS)10.3 (7.7 to 12.4)10.6 (8.4 to 13.3)
Statistical analysis
  • Non-intensive Study: Glasdegib + Azacitidine vs Non-intensive Study: Placebo + Azacitidine · Log Rank · p = 0.5955 · Hazard ratio (hr): 1.04 · 95% CI 0.775 to 1.388
SecondaryIntensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire

MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 numeric rating scale (NRS), where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.

Time frame:
Post-baseline up to Week 8
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire17.41 (12.17 to 22.66)17.24 (12.05 to 22.44)
Statistical analysis
  • Intensive Study: Glasdegib + Cytarabine + Daunorubicin vs Intensive Study: Placebo + Cytarabine + Daunorubicin · Mantel Haenszel · p = 0.5095
SecondaryNon-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12

MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.

Time frame:
Post-baseline up to Week 12
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 1211.66 (6.73 to 16.58)15.43 (9.87 to 21.00)
Statistical analysis
  • Non-intensive Study: Glasdegib + Azacitidine vs Non-intensive Study: Placebo + Azacitidine · Mantel Haenszel · p = 0.8359
SecondaryIntensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)

Complete remission (CR) was defined based on 2017 European LeukemiaNet (ELN) recommendations. CR: Bone marrow blasts \<5 percentage (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than equal to (\>=) 1.0\*10\^9/Liter (L); platelet count \>=100\*10\^9/L. CRMRD-neg: CR with negativity for a genetic marker by reverse transcription quantitative polymerase chain reaction (RT-qPCR), or CR with negativity by Multiparameter Flow Cytometry (MFC).

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)5.0 (2.4 to 9.0)5.4 (2.7 to 9.5)
SecondaryNon-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)

CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)1.8 (0.4 to 5.3)0.6 (0.0 to 3.4)
SecondaryIntensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)

CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)49.3 (42.1 to 56.4)47.3 (40.3 to 54.4)
SecondaryNon-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)

CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)19.6 (13.8 to 26.6)13.0 (8.2 to 19.1)
SecondaryIntensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)

CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC less than (\<) 1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)1.5 (0.3 to 4.3)5.4 (2.7 to 9.5)
SecondaryNon-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)

CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \<1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)2.5 (0.7 to 6.2)4.9 (2.2 to 9.5)
SecondaryIntensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)

MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)1.5 (0.3 to 4.3)2.0 (0.5 to 5.0)
SecondaryNon-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)

MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)3.1 (1.0 to 7.0)0.6 (0.0 to 3.4)
SecondaryIntensive Study: Percentage of Participants With Partial Remission (PR)

PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Number · Percentage of participants
Intensive Study: Percentage of Participants With Partial Remission (PR)
Percentage of participantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Intensive Study: Percentage of Participants With Partial Remission (PR)5.0 (2.4 to 9.0)4.4 (2.0 to 8.2)
SecondaryNon-intensive Study: Percentage of Participants With Partial Remission (PR)

PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Partial Remission (PR)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Partial Remission (PR)2.5 (0.7 to 6.2)4.9 (2.2 to 9.5)
SecondaryNon-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)

CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Number · Percentage of participants
Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
Percentage of participantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)3.1 (1.0 to 7.0)3.1 (1.0 to 7.1)
SecondaryIntensive Study: Duration of Response (DoRi)

DoRi: only defined for participants who have ever achieved CRi or better (included CR as well) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. CRi: not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. Participants last known to be alive who were free from relapse after CRi or better were censored at the date of last disease assessment that verifies their status.

Time frame:
From date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause (maximum up to 2 years)

No measurements were reported for this outcome.

SecondaryNon-intensive Study: Duration of Response (DoRi) or (DoRh)

DoRi: only defined for participants who have ever achieved CRi or better (included CR and CRh) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. DoRh: participants who had ever achieved CRh or better (included CR) on study as the time from date of first achieving CRh or better to the date of disease progression, or relapse after CRh or better, or death due to any cause. CRi: not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

Time frame:
From date of first achieving CRi/CRh or better to the date of relapse/disease progression after CRi/CRh or better or death due to any cause (maximum up to 3 years)

No measurements were reported for this outcome.

SecondaryNon-intensive Study: Time to Response

TTRi:Participants who achieved CRi or better, as the time from date of randomization to first documentation of response(CRi or better).TTRh:Participants who achieved CRh or better, as the time from date of randomization to first documentation of response(CRh or better). CRi:not qualifying for CR, neutrophil\<0.5\*10\^9/L or platelets\<50\*10\^9, absence of extramedullary disease,absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.

Time frame:
From the date of randomization to the first documentation of response (CRi/CRh or better) (maximum up to 3 years)
Reported as:
Mean · Months
Non-intensive Study: Time to Response
MonthsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
TTRi4.057 ± 1.95324.093 ± 2.1809
TTRh4.334 ± 1.88534.146 ± 2.1540
SecondaryIntensive Study: Event-free Survival (EFS)

EFS: Time from the date of randomization to the date of treatment failure (TF), relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.

Time frame:
From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 2 years)

No measurements were reported for this outcome.

SecondaryNon-intensive Study: Event-free Survival (EFS)

EFS: Time from the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.

Time frame:
From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 3 years)

No measurements were reported for this outcome.

SecondaryIntensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score

MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".

Time frame:
Day 1 up to maximum of 2 years

No measurements were reported for this outcome.

SecondaryNon-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score

MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".

Time frame:
Day 1 up to maximum of 3 years

No measurements were reported for this outcome.

SecondaryIntensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score

EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL Group. It consists of the EQ-5D descriptive system and a visual analogue scale (VAS), the EuroQoL visual analogue scale (EQ-VAS). EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.

Time frame:
Day 1 up to maximum of 2 years

No measurements were reported for this outcome.

SecondaryNon-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score

EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.

Time frame:
Day 1 up to maximum of 3 years

No measurements were reported for this outcome.

SecondaryIntensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)

EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Day 1 up to maximum of 2 years

No measurements were reported for this outcome.

SecondaryNon-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)

EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Day 1 up to maximum of 3 years

No measurements were reported for this outcome.

SecondaryIntensive Study: Participants Global Impression of Symptoms (PGIS)

PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".

Time frame:
Day 1 up to maximum of 2 years

No measurements were reported for this outcome.

SecondaryNon-intensive Study: Participants Global Impression of Symptoms (PGIS)

PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".

Time frame:
Day 1 up to maximum of 3 years

No measurements were reported for this outcome.

SecondaryIntensive Study: Participants Global Impression of Change (PGIC)

PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".

Time frame:
Day 1 up to maximum of 2 years

No measurements were reported for this outcome.

SecondaryNon-intensive Study: Participants Global Impression of Change (PGIC)

PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".

Time frame:
Day 1 up to maximum of 3 years

No measurements were reported for this outcome.

SecondaryIntensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03

AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
AEs196198
SAEs8692
Grade 3 or 4 AE173169
Grade 5 AE1620
SecondaryNon-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03

AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
AEs161158
SAEs117124
Grade 3 or 4 AE106100
Grade 5 AE5052
SecondaryIntensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03

A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Treatment related AEs181188
Treatment related SAEs4860
Grade 3 or 4 AE161149
Grade 5 AE58
SecondaryNon-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03

A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Treatment related AEs133123
Treatment related SAEs4537
Grade 3 or 4 AE9772
Grade 5 AE44
SecondaryIntensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Hematology laboratory test included: anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Anemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade)02
Anemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)2714
Anemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)113103
Anemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)45
Anemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)5273
Hemoglobin increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)02
Hemoglobin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)194194
Hemoglobin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)21
INR increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)31
Lymphocyte count decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade)02
Lymphocyte count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)04
Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)2126
Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)160152
Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)10
Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)119
Lymphocyte count increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)06
Lymphocyte count increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)185180
Lymphocyte count increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)64
Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)13
Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)10
Neutrophil count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)04
Neutrophil count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)42
Neutrophil count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)8579
Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)02
Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)105106
Platelet count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)12
Platelet count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)98100
Platelet count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)9795
White blood cell decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)14
White blood cell decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)32
White blood cell decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)155156
White blood cell decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)3735
SecondaryNon-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Hematology laboratory test included: anemia, hemoglobin increased, INR increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Anemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)2941
Anemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)9787
Anemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)51
Anemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)2931
Hemoglobin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)160159
Hemoglobin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)01
Lymphocyte count decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade)20
Lymphocyte count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)10
Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)9689
Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)5154
Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)24
Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)713
Lymphocyte count increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)30
Lymphocyte count increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)147157
Lymphocyte count increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)73
Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)20
Neutrophil count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)40
Neutrophil count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)1322
Neutrophil count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)4840
Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)21
Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)9297
Platelet count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)2128
Platelet count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)5564
Platelet count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)10
Platelet count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)8368
White blood cell decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade)10
White blood cell decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)10
White blood cell decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)4348
White blood cell decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)7062
White blood cell decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
White blood cell decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)4548
SecondaryIntensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, creatine phosphokinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Alanine aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)11
Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)175184
Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)1613
Alanine aminotransferase increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)10
Alkaline phosphatase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)23
Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)187192
Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)23
Aspartate aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)52
Aspartate aminotransferase increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)01
Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)173186
Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)159
Blood bilirubin increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)03
Blood bilirubin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)184189
Blood bilirubin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)85
Blood bilirubin increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)01
Chronic kidney disease: Missing (baseline grade) to Grade <=2 (CTCAE grade)45
Chronic kidney disease: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)182188
Chronic kidney disease: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)84
Chronic kidney disease: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)10
Chronic kidney disease: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)01
CPK increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)2019
CPK increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)161166
CPK increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)20
Creatinine increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)188192
Creatinine increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)76
GGT increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)57
GGT increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)811
GGT increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)02
Hypercalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)15
Hypercalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)191192
Hyperglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)13
Hyperglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)174183
Hyperglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)1510
Hyperglycemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)21
Hyperglycemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)21
Hyperkalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)194194
Hyperkalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)23
Hyperkalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hypermagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)24
Hypermagnesemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade)01
Hypermagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)190184
Hypermagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)12
Hypermagnesemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hypernatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)196196
Hypernatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)01
Hypernatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hypoalbuminemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)03
Hypoalbuminemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade)11
Hypoalbuminemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)185185
Hypoalbuminemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)58
Hypoalbuminemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)11
Hypocalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)15
Hypocalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)190189
Hypocalcemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)13
Hypoglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)13
Hypoglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)193194
Hypoglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)01
Hypokalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)155159
Hypokalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)4137
Hypokalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)02
Hypomagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)25
Hypomagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)190187
Hypomagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)10
Hyponatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)177188
Hyponatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)178
Hyponatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)11
Hyponatremia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)11
Hypophosphatemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)33
Hypophosphatemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade)11
Hypophosphatemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)153153
Hypophosphatemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade3333
Hypophosphatemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)02
Hypophosphatemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)31
SecondaryNon-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, CPK increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Alanine aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)20
Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)152154
Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)66
Alanine aminotransferase increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)00
Alkaline phosphatase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)01
Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)159157
Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)01
Aspartate aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)30
Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)152156
Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)44
Blood bilirubin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)157159
Blood bilirubin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)31
Chronic kidney disease: Missing (baseline grade) to Grade <=2 (CTCAE grade)21
Chronic kidney disease: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)130134
Chronic kidney disease: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)2823
Chronic kidney disease: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)02
CPK increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)98
CPK increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)147147
CPK increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)12
Creatinine increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)153155
Creatinine increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)75
GGT increased: Missing (baseline grade) to Grade <=2 (CTCAE grade)35
GGT increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade)43
GGT increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)10
Hypercalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)22
Hypercalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)156158
Hyperglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)24
Hyperglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)147136
Hyperglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)814
Hyperglycemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)22
Hyperkalemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)20
Hyperkalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)155157
Hyperkalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)23
Hyperkalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)00
Hyperkalemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)00
Hypermagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)24
Hypermagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)155154
Hypermagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)22
Hypernatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)158159
Hypernatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)21
Hypoalbuminemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)20
Hypoalbuminemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)151157
Hypoalbuminemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)63
Hypocalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)22
Hypocalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)154155
Hypocalcemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)13
Hypocalcemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)00
Hypoglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)24
Hypoglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)155156
Hypoglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)30
Hypokalemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)20
Hypokalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)129139
Hypokalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)2315
Hypokalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)12
Hypokalemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)44
Hypomagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)24
Hypomagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)151153
Hypomagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)62
Hypomagnesemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hyponatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)135142
Hyponatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade)2415
Hyponatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hyponatremia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)12
Hypophosphatemia: Missing (baseline grade) to Grade <=2 (CTCAE grade)32
Hypophosphatemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade)10
Hypophosphatemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade)141138
Hypophosphatemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade1217
Hypophosphatemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade)01
Hypophosphatemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade)12
SecondaryIntensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 0 (CTCAE grade)10
Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 1 (CTCAE grade)01
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 0 (CTCAE grade)04
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 1 (CTCAE grade)12
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 2 (CTCAE grade)01
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 3 (CTCAE grade)10
Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 1 (CTCAE grade)11
INR increased: Missing (baseline grade) to Grade 0 (CTCAE grade)11
INR increased: Missing (baseline grade) to Grade 1 (CTCAE grade)01
INR increased: Missing (baseline grade) to Grade 2 (CTCAE grade)10
INR increased: Grade 0 (baseline grade) to Grade 0 (CTCAE grade)02
INR increased: Grade 0 (baseline grade) to Grade 1 (CTCAE grade)10
INR increased: Grade 0 (baseline grade) to Grade 2 (CTCAE grade)11
INR increased: Grade 0 (baseline grade) to Grade 3 (CTCAE grade)01
INR increased: Grade 1 (baseline grade) to Grade 0 (CTCAE grade)01
INR increased: Grade 1 (baseline grade) to Grade 1 (CTCAE grade)03
INR increased: Grade 1 (baseline grade) to Grade 2 (CTCAE grade)11
INR increased: Grade 1 (baseline grade) to Grade 3 (CTCAE grade)10
SecondaryNon-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03

Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 0 (CTCAE grade)10
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 0 (CTCAE grade)85
Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 1 (CTCAE grade)57
Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 0 (CTCAE grade)10
Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 1 (CTCAE grade)10
Activated partial thromboplastin time prolonged: Grade 2 (baseline grade) to Grade 1 (CTCAE grade)10
INR increased: Missing (baseline grade) to Grade 0 (CTCAE grade)10
INR increased: Grade 0 (baseline grade) to Grade 0 (CTCAE grade)45
INR increased: Grade 0 (baseline grade) to Grade 1 (CTCAE grade)64
INR increased: Grade 0 (baseline grade) to Grade 2 (CTCAE grade)12
INR increased: Grade 0 (baseline grade) to Grade 3 (CTCAE grade)10
INR increased: Grade 1 (baseline grade) to Grade 1 (CTCAE grade)11
INR increased: Grade 1 (baseline grade) to Grade 2 (CTCAE grade)20
INR increased: Grade 3 (baseline grade) to Grade 1 (CTCAE grade)11
SecondaryIntensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib

Ctrough of Glasdegib was measured in nanogram per milliliter (ng/mL).

Time frame:
Induction, Day 10+/-1: pre-dose, 1, 4 hour (hr); Consolidation phase, Day 1: pre-dose, 1, 4 hr
Reported as:
Geometric mean · ng/ml
Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
ng/mlIntensive Study: Glasdegib + Cytarabine + Daunorubicin
Induction Day 10413.54 ± 125
Consolidation 1, Day 1245.48 ± 80
Consolidation 2, Day 1259.79 ± 122
SecondaryNon-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib

Ctrough of Glasdegib was measured in ng/mL.

Time frame:
Pre-dose: Cycle 1 Day 15 and Cycle 2 Day 1
Reported as:
Geometric mean · ng/ml
Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
ng/mlNon-intensive Study: Glasdegib + Azacitidine
Cycle 1 Day 15565.44 ± 126
Cycle 2 Day 1472.42 ± 122
SecondaryIntensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 2 years
Reported as:
Count of participants · Participants
Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
ParticipantsIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + Daunorubicin
QTcB: <=450 msec (baseline) to <=450 msec (post-baseline)5171
QTcB: <=450 msec (baseline) to >450-<=480 msec (post-baseline)6463
QTcB: <=450 msec (baseline) to >480-<=500 msec (post-baseline)1811
QTcB: <=450 msec (baseline) to >500 msec (post-baseline)116
QTcB: >450-<=480 msec (baseline) to <=450 msec (post-baseline)23
QTcB: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline)2017
QTcB: >450-<=480 msec (baseline) to >480-<=500 msec (post-baseline)1610
QTcB: >450-<=480 msec (baseline) to >500 msec (post-baseline)15
QTcB: >480-<=500 msec (baseline) to >450-<=480 msec (post-baseline)10
QTcB: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline)21
QTcB: >480-<=500 msec (baseline) to >500 msec (post-baseline)10
QTcB: >500 msec (baseline) to >500 msec (post-baseline)11
QTcF: <=450 msec (baseline) to <=450 msec (post-baseline)116132
QTcF: <=450 msec (baseline) to >450-<=480 msec (post-baseline)5039
QTcF: <=450 msec (baseline) to >480-<=500 msec (post-baseline)810
QTcF: <=450 msec (baseline) to >500 msec (post-baseline)50
QTcF: >450-<=480 msec (baseline) to <=450 msec (post-baseline)21
QTcF: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline)55
QTcF: >450-<=480 msec (baseline) to >500 msec (post-baseline)11
QTcF: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline)01
SecondaryNon-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.

Time frame:
Day 1 up to maximum of 3 years
Reported as:
Count of participants · Participants
Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
ParticipantsNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
QTcB: <=450 msec (baseline) to <=450 msec (post-baseline)4858
QTcB: <=450 msec (baseline) to >450-<=480 msec (post-baseline)5343
QTcB: <=450 msec (baseline) to >480-<=500 msec (post-baseline)611
QTcB: <=450 msec (baseline) to >500 msec (post-baseline)73
QTcB: >450-<=480 msec (baseline) to <=450 msec (post-baseline)01
QTcB: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline)2022
QTcB: >450-<=480 msec (baseline) to >480-<=500 msec (post-baseline)138
QTcB: >450-<=480 msec (baseline) to >500 msec (post-baseline)53
QTcB: >480-<=500 msec (baseline) to >450-<=480 msec (post-baseline)12
QTcB: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline)31
QTcB: >480-<=500 msec (baseline) to >500 msec (post-baseline)23
QTcF: <=450 msec (baseline) to <=450 msec (post-baseline)100104
QTcF: <=450 msec (baseline) to >450-<=480 msec (post-baseline)3936
QTcF: <=450 msec (baseline) to >480-<=500 msec (post-baseline)70
QTcF: >450 - <=480 (baseline) to <=450msec (post-baseline)11
QTcF: >450 - <=480 msec (baseline) to >450 - <=480msec(post baseline)01
QTcF: >450 - <=480 msec (baseline) to >480 - <=500 msec (post baseline)58
QTcF: >480 msec (baseline) to <=500 msec (post baseline)14
QTcF: >450 - <=480 (baseline) to >500 msec (post baseline)11
QTcF: >480 - <=500msec (baseline) to >480 - <=500 msec (post baseline)10

Adverse events

Collected over Intensive study: Day 1 up to maximum of 2 years; non-intensive study: Day 1 up to maximum of 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intensive Study: Glasdegib + Cytarabine + Daunorubicin90/201 (44.8%)86/198 (43.4%)194/198 (98%)
Intensive Study: Placebo + Cytarabine + Daunorubicin88/203 (43.3%)92/201 (45.8%)195/201 (97%)
Non-intensive Study: Glasdegib + Azacitidine117/163 (71.8%)117/162 (72.2%)154/162 (95.1%)
Non-intensive Study: Placebo + Azacitidine113/162 (69.8%)124/160 (77.5%)148/160 (92.5%)
Most frequent serious events
Showing 10 of 258
Most frequent serious events
EventIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
PneumoniaInfections and infestations15/19811/20129/16236/160
Febrile neutropeniaBlood and lymphatic system disorders18/19817/20124/16220/160
Disease progressionGeneral disorders2/1985/20114/16222/160
SepsisInfections and infestations15/19813/20114/16210/160
PyrexiaGeneral disorders4/1986/20111/16211/160
Electrocardiogram QT prolongedInvestigations13/1988/2015/1623/160
Urinary tract infectionInfections and infestations0/1981/2019/1624/160
CellulitisInfections and infestations1/1980/2012/1627/160
Septic shockInfections and infestations2/1984/2014/1627/160
AnaemiaBlood and lymphatic system disorders2/1981/2016/1625/160
Most frequent other events
Showing 10 of 76
Most frequent other events
EventIntensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + Azacitidine
NauseaGastrointestinal disorders110/198106/20158/16244/160
AnaemiaBlood and lymphatic system disorders101/19897/20173/16271/160
Febrile neutropeniaBlood and lymphatic system disorders97/19896/20123/16222/160
DiarrhoeaGastrointestinal disorders96/19888/20139/16232/160
PyrexiaGeneral disorders84/19884/20142/16238/160
HypokalaemiaMetabolism and nutrition disorders76/19883/20135/16222/160
Platelet count decreasedInvestigations77/19873/20130/16226/160
ConstipationGastrointestinal disorders71/19861/20158/16252/160
White blood cell count decreasedInvestigations63/19853/20117/16218/160
VomitingGastrointestinal disorders57/19840/20135/16232/160

Baseline characteristics

Full analysis (FA) set included all randomized participants.

Age, Continuous
Age, Continuous(years)Intensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + AzacitidineTotal
Mean56.55 ± 12.6055.38 ± 13.6173.19 ± 7.1773.14 ± 6.8263.63 ± 13.79
Sex: Female, Male
Sex: Female, Male(Participants)Intensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + AzacitidineTotal
Female71979789354
Male1301066673375
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + AzacitidineTotal
Hispanic or Latino1912121659
Not Hispanic or Latino166171140139616
Unknown or Not Reported162011754
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intensive Study: Glasdegib + Cytarabine + DaunorubicinIntensive Study: Placebo + Cytarabine + DaunorubicinNon-intensive Study: Glasdegib + AzacitidineNon-intensive Study: Placebo + AzacitidineTotal
American Indian or Alaska Native10001
Asian66575144218
Native Hawaiian or Other Pacific Islander00000
Black or African American331714
White1101239799429
More than one race10001
Unknown or Not Reported2020141266
08

Study locations

149 sites
  • UCLA Department of Medicine
    Los Angeles, California 90095, United States
  • UCLA Drug Information/Investigational Drugs
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology Clinic
    Los Angeles, California 90095, United States
  • UCLA Ronald Reagan Medical Center
    Los Angeles, California 90095, United States
  • UC Irvine Health - Chao Family Comprehensive Cancer Center
    Orange, California 92868-3201, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94143, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • UCLA Hematology/Oncology - Westlake Village
    Westlake Village, California 91361, United States
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
  • Georgia Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
  • Tufts Medical Center Investigational Drug Pharmacy
    Boston, Massachusetts 02111, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • MidAmerica Division, Inc., c/o Research Medical Center
    Kansas City, Missouri 64132, United States
  • Northwell Health/Monter Cancer Center
    Lake Success, New York 11042, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • TriStar Bone Marrow Transplant
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Blood Cancer and Stem Cell Transplant Clinic
    San Antonio, Texas 78229, United States
  • Methodist Healthcare System of San Antonio
    San Antonio, Texas 78229, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU
    Salzburg, 5020, Austria
  • Uniklinikum Salzburg, Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel
    Wien, 1130, Austria
  • AZ Sint-Jan Brugge-Oostende av
    Brugge, B-8000, Belgium
  • Universitaire Ziekenhuizen Brussel (UZ Brussel)
    Brussels, B-1090, Belgium
  • Universitaire Ziekenhuizen Brussel
    Brussels, B-1090, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, B-3000, Belgium
  • Health Sciences Centre
    Winnipeg, Manitoba R3A 1R9, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l'Est-de-l'Ile-de- Montréal - Hôpital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • The First Affiliated Hospital of USTC, Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • Anhui Provincial Hospital
    Hefei, Anhui 230071, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Guangdong Second Provincial General Hospital
    Guangzhou, Guangdong 510317, China
  • Hebei Yanda Lu Daopei Hospital
    Langfang, Hebei 065201, China
  • Henan Provincial People's Hospital/Hematology Department
    Zhengzhou, Henan 450003, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology/Cancer Center
    Wuhan, Hubei 430030, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
  • The First Affiliated Hospital College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
  • Interni hematologicka a onkologicka klinika, Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Nemocnicni lekarna
    Brno, 625 00, Czechia
  • Ustavni lekarna
    Ostrava - Poruba, 708 52, Czechia
  • Klinika hematoonkologie
    Ostrava-Poruba, 708 52, Czechia
  • Interní hematologická klinika, Fakultni nemocnice Královské Vinohrady
    Praha 10, 100 34, Czechia
  • Ústavni lékárna
    Praha 10, 100 34, Czechia
  • CHU Henri Mondor
    Créteil, 94010, France
  • CHU de Nantes
    Nantes cedex 1, 44093, France
  • CHU de Nantes Hotel Dieu
    Nantes cedex, 44093, France
  • Hopital Saint Louis
    Paris, 75010, France
  • Centre Hospitalier Lyon Sud - Service d'Hematologie
    Pierre-Benite cedex, 69495, France
  • Institut Gustave Roussy
    Villejuif cedex, 94805, France
  • Klinikum der Universitaet Muenchen
    Munich, Bavaria 81377, Germany
  • Philipps-Universitaet Marburg
    Marburg, Hesse 35032, Germany
  • Universitätsklinikum Köln
    Koeln, North Rhine Westphalia 50937, Germany
  • Universitaetsklinikum Muenster
    Muenster, North Rhine-westphalia 48149, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek
    Debrecen, 4032, Hungary
  • Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika
    Debrecen, 4032, Hungary
  • Petz Aladár Megyei Oktató Kórház, II. Belgyógyászat- Hematológiai Osztály
    Győr, 9024, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz, Hematologia
    Nyiregyhaza, 4400, Hungary
  • Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz,
    Nyiregyhaza, 4400, Hungary
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center (Ein Kerem)
    Jerusalem, 91120, Israel
  • Hemato-oncology ambulatory Service
    Petah Tikva, 4941492, Israel
  • Rabin Medical Center, Beilinson Hospital
    Petah Tikva, 4941492, Israel
  • AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi, Clinica Di Ematologia
    Torrette Di Ancona, Ancona 60126, Italy
  • SOD Farmacia-Dipt dei servizi -AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi
    Torette Di Ancona, AN 60126, Italy
  • A.O.U. di Ferrara- Arcispedale Sant'Anna,
    Cona, Ferrara, FE 44124, Italy
  • AO Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro -
    Pesaro, PU 61122, Italy
  • Azienda Ospedaliera Universitaria Senese.
    Siena, SI 53100, Italy
  • Azienda Ospedaliero Universitaria di Bologna Policlinico S.Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera Universitaria Senese
    Siena, 53100, Italy
  • Japanese Red Cross Nagoya Daini Hospital
    Nagoya, Aichi 466-8650, Japan
  • University of Fukui Hospital
    Yoshida-gun, Fukui 910-1193, Japan
  • Gunma University Hospital
    Maebashi, Gunma 371-8511, Japan
  • Kobe University Hospital
    Kobe-shi, Hyogo 650-0017, Japan

Showing the first 100 of 149 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13. PubMed 31516032 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jun 2020, 25 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 25 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2017
First posted
Jan 31, 2018
StartActual
Apr 20, 2018
Primary completionActual
Jun 5, 2020
CompletionActual
Jan 17, 2022
Results first posted
Jun 25, 2021
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03416179
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Apr 20, 2018
Primary completion
Jun 5, 2020
Completion
Jan 17, 2022
Results posted
Jun 25, 2021
Last update
Apr 21, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glasdegib · Daunorubicin · Cytarabine · Azacitidine

Start the discussion